Clinical trials: COVID-19 Vaccines
Chronic Liver Disease
Antibody Response to COVID-19 Vaccines in Liver Disease Patients
Currently the Pfizer-Biontech (mRNA), Sinovac (inactivated virus) and Astrazeneca-Oxford (adenovirus-vector) COVID-19 vaccines are available for vaccination in HK.
- Trial name
- NCT04775069
- Testing
- BNT162b2, CoronaVac, AZD1222
- Where
- Hong Kong
- Volunteers
- 232 people
- Sponsor
- Humanity & Health Medical Group Limited
Spinal Cord Injuries, Traumatic Spinal Cord Injury
SCIVAX: Biomarkers of Immune Dysfunction and Vaccine Responsiveness in Chronic SCI
The purpose of this observational research study is to better understand immune responses to vaccines against viruses (influenza or SARS-CoV2).
- Conditions
- Spinal Cord Injuries, Traumatic Spinal Cord Injury, Healthy Controls, Flu Vaccine
- Trial name
- SCIVAX (NCT05869968)
- Where
- United States
- Volunteers
- 140 people, healthy volunteers welcome
- Sponsor
- Northwell Health
COVID-19 Prevention
Study to Evaluate Efficacy, Immunogenicity and Safety of the Sputnik-Light
The study Global sponsor is planning several parallel studies of Sputnik-Light vector vaccine across the globe in United Arab Emirates, Russia and possibly in other countries in case of confirmation associated with the same…
- Trial name
- SPUTNIK-LIGHT (NCT04741061)
- Testing
- Sputnik Light
- Where
- 15 sites in Russia
- Volunteers
- 6,000 people, healthy volunteers welcome
- Sponsor
- Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation
COVID-19, Sars-CoV-2 Infection
A Phase II Clinical Trial to Evaluate the Immunogenicity and Safety of SCTV01E in Population Aged ≥18 Years Previously Fully Vaccinated With mRNA COVID-19 Vaccine
The objective of this study is to evaluate the immunogenicity and safety of SCTV01E in participants aged ≥18 years and previously fully immunized with mRNA COVID-19 vaccine.
- Trial name
- NCT05238441
- Testing
- SCTV01E, Comirnaty
- Volunteers
- 360 people, healthy volunteers welcome
- Sponsor
- Sinocelltech Ltd.
COVID-19, Chronic Bronchitis
Immunogenicity and Safety of an Inactivated COVID-19 Vaccine in Patients Aged ≥60 Years With Chronic Bronchitis and COPD
Evaluation of immunogenicity and safety of the subjects aged 60 years and above with chronic bronchitis and chronic obstructive pulmonary disease recruited to receive the schedule of three doses of inactivated COVID-19 vaccine on…
- Conditions
- COVID-19, Chronic Bronchitis, Copd
- Trial name
- NCT05075057
- Testing
- Inactivated COVID-19 vaccine
- Where
- China
- Volunteers
- 400 people
- Sponsor
- China National Biotec Group Company Limited
COVID-19 Vaccine
Evaluation of the Safety, Tolerability, and Reactogenicity of the Baiya SARS-CoV-2 Vax 2 Vaccine for COVID-19 Disease
The investigational product Baiya SARS-CoV-2 Vax 2 vaccine is a second-generation of protein subunit vaccine from plant. The primary objective aiming to evaluate the safety, tolerability, and reactogenicity of Baiya SARS-CoV-2…
- Trial name
- NCT05197712
- Testing
- 25 Baiya SARS-CoV-2 Vax 2, 50 Baiya SARS-CoV-2 Vax 2
- Where
- Thailand
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Baiya Phytopharm Co., Ltd.
Coronavirus Infection
The Study of "Gam-COVID-Vac" Vaccine Against COVID-19 With the Participation of Volunteers of 60 y.o and Older
The purpose of this study: to assess the safety, tolerability and immunogenicity of the drug "Gam-COVID-Vac", a solution for intramuscular injection, at various times after vaccination in volunteers over 60 years of age
- Trial name
- NCT04587219
- Testing
- Gam-COVID-Vac
- Where
- Russia
- Volunteers
- 110 people, healthy volunteers welcome
- Sponsor
- Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation
Covid19, BCG Vaccination Reaction
Clinical Trial Evaluating the Effect of BCG Vaccination on the Incidence and Severity of SARS-CoV-2 Infections Among Healthcare Professionals During the COVID-19 Pandemic in Poland
Countries that have not carried out universal mass vaccination against tuberculosis (BCG) have been shown to have higher incidence and death rates due to COVID-19 than countries with mass, long-term BCG immunization programmes.
- Conditions
- Covid19, BCG Vaccination Reaction, SARS-CoV Infection
- Trial name
- NCT04648800
- Testing
- BCG-10 vaccine, 0.9% saline
- Where
- 6 sites in Poland
- Volunteers
- 1,000 people, healthy volunteers welcome
- Sponsor
- Hanna Czajka
COVID-19
Immunogenicity and Safety Study of One Booster Dose of Trivalent COVID-19 Vaccine (Vero Cell), Inactivated
This is a randomized, double-blind, active-controlled phase Ⅲ clinical trial.The purpose of this study is to evaluate the immunogenicity and safety of one booster dose of trivalent COVID-19 vaccine (vero cell), inactivated…
- Trial name
- NCT05433272
- Testing
- Trivalent COVID-19 Vaccine (Vero Cell), Inactivated, Prototype Strain, Delta Strain and Omicron Strain, COVID-19 Vaccine (Vero Cell), Inactivated
- Where
- Colombia
- Volunteers
- 1,400 people, healthy volunteers welcome
- Sponsor
- Sinovac Biotech (Colombia) S.A.S.
SARS-CoV 2
Safety, Tolerability and Immunogenicinity of a Coronavirus-Like Particle COVID-19 Vaccine in Adults Aged 18-55 Years.
The study will be a randomized, partially-blinded, prime-boost, staggered dose-escalation Phase 1 study intended to assess the safety, tolerability, and immunogenicity of the Coronavirus-Like Particle COVID-19 Vaccine at three…
- Trial name
- NCT04450004
- Testing
- Intramuscular Vaccine
- Where
- 2 sites in Canada
- Volunteers
- 180 people, healthy volunteers welcome
- Sponsor
- Medicago
SARS-CoV-2, COVID-19
A Study of the Effectiveness of Moderna COVID-19 Vaccine
This is an observational cohort study to evaluate real-world vaccine effectiveness and durability of Moderna COVID-19 vaccine among a diverse population at Kaiser Permanente Southern California (KPSC).
- Trial name
- NCT05933304
- Where
- United States
- Volunteers
- 927,004 people, healthy volunteers welcome
- Sponsor
- ModernaTX, Inc.
COVID-19, Vaccine Hesitancy
Online Games to Help Canadian and U.S. Adults Identify COVID-19 and Vaccine Misinformation: Three Sequential Randomized Studies
COVID-19 misinformation contributed to vaccine hesitancy and preventable illness. This record covers three sequential randomized studies (conducted in Canada and the United States, November-December 2020) testing whether a brief…
- Conditions
- COVID-19, Vaccine Hesitancy, Health Misinformation, Communication
- Trial name
- NCT07758309
- Testing
- Gamified misinformation refutation quiz, Refutational text (active control)
- Where
- United States
- Volunteers
- 3,637 people, healthy volunteers welcome
- Sponsor
- University of South Carolina
SARS CoV 2 Infection
A Phase IV Vaccine Study Under the National Cohort Study of Effectiveness and Safety of SARS-CoV-2 (COVID-19) Vaccines.
A phase IV study to assess if the SARS-CoV-2 vaccine from Johnson \& Johnson/Janssen (J\&J) results in change in number and activation of platelets and anti-PF4 Level.
- Trial name
- NCT06360744
- Testing
- Johnson & Johnson
- Where
- 5 sites in Denmark
- Volunteers
- 25 people, healthy volunteers welcome
- Sponsor
- Jens D Lundgren, MD
SARS-CoV-2
Post-marketing Surveillance (PMS) Use-Result Surveillance With SPIKEVAX BIVALENT, SPIKEVAX X Injection, SPIKEVAX JN Injection and SPIKEVAX IN PRE-FILLED SYRINGE
The main objective of the surveillance is to evaluate the incidence of the adverse events (AEs), and other safety-related information in South-Korean population.
- Trial name
- NCT06333704
- Testing
- SPIKEVAX Bivalent BA.1, SPIKEVAX Bivalent BA.4/5, SPIKEVAX XBB.1.5
- Where
- 26 sites in South Korea
- Volunteers
- 4,207 people, healthy volunteers welcome
- Sponsor
- ModernaTX, Inc.
COVID-19
Safety and Immunogenicity Study of AdCLD-CoV19: A COVID-19 Preventive Vaccine in Healthy Volunteers
This is a Phase 1/2a clinical trial to assess the safety and immunogenicity of AdCLD-CoV19 in healthy adults.
- Trial name
- NCT04666012
- Testing
- AdCLD-CoV19
- Where
- 5 sites in South Korea
- Volunteers
- 150 people, healthy volunteers welcome
- Sponsor
- Cellid Co., Ltd.
COVID-19, SARS-CoV-2 Infection
Whole-Virion Inactivated SARS-CoV-2 Vaccine (BBV152) for COVID-19 in Healthy Volunteers
Double blind, Multi-Centre study to evaluate the safety, reactogenicity, tolerability, and immunogenicity of three investigational vaccine groups and one placebo group in healthy volunteers who receive two intramuscular doses of…
- Trial name
- BBV152 (NCT04471519)
- Testing
- BBV152A - Phase I, BBV152B - Phase I, BBV152C - Phase I
- Where
- 12 sites in India
- Volunteers
- 755 people, healthy volunteers welcome
- Sponsor
- Bharat Biotech International Limited
COVID-19
Phase III Trial of A COVID-19 Vaccine of Adenovirus Vector in Adults 18 Years Old and Above
This study is a global multicenter, randomized, double-blind, placebo -controlled, adaptive designed phase Ⅲ clinical trial, in order to evaluate the efficacy, safety and immunogenicity of Recombinant Novel Coronavirus Vaccine…
- Trial name
- NCT04526990
- Testing
- Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector)
- Where
- 74 sites in Argentina, Chile and 3 more
- Volunteers
- 44,247 people, healthy volunteers welcome
- Sponsor
- CanSino Biologics Inc.
Coronavirus, Covid19
A Dose-Confirmation Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Vaccine CVnCoV in Healthy Adults for COVID-19
This study aims to evaluate the safety and reactogenicity profile after 1 and 2 dose administrations of investigational SARS-CoV-2 mRNA vaccine (CVnCoV) at different dose levels and to evaluate the humoral immune response after 1…
- Conditions
- Coronavirus, Covid19, SARS-CoV-2, Severe Acute Respiratory Syndrome
- Trial name
- NCT04515147
- Testing
- CVnCoV 6 μg, CVnCoV 12 μg, Hepatitis A vaccine
- Where
- 2 sites in Panama, Peru
- Volunteers
- 668 people, healthy volunteers welcome
- Sponsor
- CureVac
Healthy
Study Comparing Safety and Immunogenicity of Intranasal COVID-19 Vaccine and mRNA Booster in Healthy Adults
This Phase I/II trial in France evaluates safety and immunogenicity of a booster dose of an intranasal COVID-19 vaccine (LVT-001) versus a booster dose of a COVID-19 mRNA vaccine (Pfizer-BioNTech) in healthy adult volunteers.
- Trial name
- MUCOBOOST (NCT06821126)
- Testing
- LVT-001, Cormirnaty
- Where
- 5 sites in France
- Volunteers
- 238 people, healthy volunteers welcome
- Sponsor
- ANRS, Emerging Infectious Diseases
COVID-19
Booster Study of COVID-19 Protein Subunit Recombinant Vaccine
Observer-blind, randomized, active-controlled prospective intervention study of Immunogenicity \& Safety of SARS-Cov-2 Protein Subunit Recombinant Vaccine (Bio Farma) as a Booster Dose Against COVID-19 in Adults 18 Years of Age…
- Trial name
- NCT05525208
- Testing
- SARS-CoV-2 subunit protein recombinant vaccine, Active Comparator
- Where
- 2 sites in Indonesia
- Volunteers
- 696 people, healthy volunteers welcome
- Sponsor
- PT Bio Farma